This trial was the first Ebola or Marburg vaccine clinical trial in Africa, and the results showed that, given separately or together, both vaccines were well tolerated and elicited antigen-specific humoral and cellular immune responses, thus contributing to expedited development of more potent Ebola virus vaccines that use the same wild-type glycoprotein antigens28. This evidence concerns the gene ART4 and Ebola hemorrhagic fever.